VBIV - VBI Vaccines, Inc. Price/Earnings to Growth Ratio

Brandmark of VBI Vaccines Inc. (VBIV)

The price-to-earnings ratio relative to projected EPS growth for VBI Vaccines Inc. (VBIV) is adjusting due to the delegation of tests to external CROs, which eliminates operational disruptions. Growth is based on the eVLP platform, which creates unique vaccines, and automated biosynthesis, which guarantees drug purity. The current mark of 0.00 indicates the asset's market value level, allowing the investor to assess the degree of the company's undervaluation relative to profit growth rates.

VBI Vaccines, Inc. (VBIV): Price/Earnings to Growth Ratio from 07/04/2022 to 08/17/2024

Metric breakdowns and analytics for VBI Vaccines Inc (VBIV)

- share price and consensus valuation forecast:
- market capitalization statistics:
Summary company analytics:VBI Vaccines Inc VBIV
Signature product of VBI Vaccines, Inc.

Developing innovative cancer and hepatitis B vaccines requires the recruitment of leading immunologists, whose scientific achievements directly determine the future capitalization of VBI Vaccines Inc. (VBIV). By analyzing the PEG momentum indicator, an investor compares the current P/E multiple with the earnings growth rate: a value below one signals that the asset is undervalued relative to its expansion, making it possible to identify potentially explosive growth in business value.